MedTrace Logo

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.

NCT03381209 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-12-21

No results posted yet for this study

Summary

The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.

Conditions

  • Muscle Relaxation

Interventions

DRUG

Sugammadex

sugammadex given based on 3 measurements of body weights

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Walid Nofal, MD · Anesthesiology department, Faculty of Medicine, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-10
Primary Completion
2017-11-10
Completion
2017-11-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381209 on ClinicalTrials.gov